Nalfurafine
![]() | |
Systematic (IUPAC) name | |
---|---|
(2E)-N-[(5α,6β)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5-epoxymorphinan- 6-yl]- 3-(3-furyl)- N-methylacrylamide | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
intravenous | |
Identifiers | |
152658-17-8 ![]() | |
V03AX02 | |
PubChem | CID 6445230 |
IUPHAR ligand | 1651 |
ChemSpider |
4949003 ![]() |
UNII |
XC41AVD567 ![]() |
ChEMBL |
CHEMBL267495 ![]() |
Synonyms | TRK-820 |
Chemical data | |
Formula | C28H32N2O5 |
476.564 g/mol | |
SMILES
| |
| |
![]() |
Nalfurafine (INN and USAN;[1] also known as AC-820, TRK-820; trade name Remitch) is a κ-opioid receptor agonist marketed as a treatment for uremic pruritus in people undergoing hemodialysis.[2]
As of January 2010, it is also being investigated for the treatment of pruritus in patients with chronic liver disease.[3]
References
- ↑ Statement on a Nonproprietary Name adopted by the USAN Council
- ↑ "AC-820". Acologix. 2009.
- ↑ Clinical trial number NCT00638495 for "Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease" at ClinicalTrials.gov